Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 8/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | BMI1 | P35226 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001480 | 0.86 | PAK4 (0.41) | MAP3K14TTBK1PAK4PRKD1CDC7 | |
| SCHEMBL11970796 | 0.83 | PAK4 (0.61) | MAP3K14TTBK1PAK4PRKD1PIKFYVE | |
| SCHEMBL11970783 | 0.81 | MAP3K14 (0.50) | MAP3K14TTBK1PAK4CDC7CDK2 | |
| SCHEMBL12001441 | 0.78 | MAP3K14 (0.59) | MAP3K14TTBK1PAK4PRKD1CDC7 | |
| SCHEMBL12489655 | 0.78 | MAP3K14 (0.41) | MAP3K14TTBK1PAK4PRKD1CDC7 | |
| SCHEMBL12001575 | 0.78 | MAP3K14 (0.44) | MAP3K14TTBK1PAK4PRKD1CDC7 | |
| SCHEMBL11970997 | 0.77 | PAK4 (0.62) | MAP3K14PAK4PRKD1PIKFYVE | |
| SCHEMBL12525986 | 0.75 | MAP3K14 (0.63) | MAP3K14ROCK1 | |
| SCHEMBL12001656 | 0.74 | PAK4 (0.73) | MAP3K14TTBK1PAK4PRKD1CDC7 | |
| SCHEMBL12001663 | 0.73 | PAK4 (0.53) | MAP3K14PAK4BMI1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | MAP3K14 519/4885TTBK1 915/4885PAK4 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.